AIT Therapeutics Announces Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria Patients

AIT Therapeutics (OTC:AITB) a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with serious lung infections and pulmonary hypertension, today announced positive data at Day 81, the end of its NO-NTM Abscessus clinical trial.
As quoted in the press release:

“We continue to be delighted with the data from this trial.  With just 21 days of treatment patients are still benefitting at Day 81 as shown by 6-minute walk data.  Additionally, the anti-microbial effect of NO is apparent with qPCR showing a 65% reduction in bacterial load,” said Steve Lisi, Chairman and Chief Executive Officer of AIT Therapeutics.  “Our proprietary system with our NO generator may allow AIT to treat patients at home for an extended period of time, possibly at a higher NO concentration, potentially improving on the strong results shown in our completed study.”

Click here to read the full press release.